Kelsey Rothenberg, PA
Medical · Durham, NCNPI 1083252357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 598 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 26.7% of the total. Among medical clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 598 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$1K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$466
- plus $2K from 18 others
What the payments were for
- Food & beverage$9,43795%
- Education$4795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 186 | $2,649 |
| AbbVie | 117 | $1,466 |
| Alkermes, Inc. | 61 | $1,170 |
| Neurocrine Biosciences, Inc. | 54 | $1,045 |
| Johnson & Johnson(2 entities) | 32 | $1,003 |
| Otsuka America Pharmaceutical, Inc. | 24 | $466 |
| Lundbeck LLC | 20 | $357 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $333 |
| Vanda Pharmaceuticals Inc. | 17 | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $213 |
| Actelion Pharmaceuticals US, Inc. | 3 | $170 |
| Indivior Inc. | 8 | $151 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Sunovion Pharmaceuticals Inc. | 5 | $104 |
| Supernus Pharmaceuticals, Inc. | 4 | $71 |
| Merck | 5 | $71 |
| Neos Therapeutics, LP | 4 | $59 |
| Avanir Pharmaceuticals, Inc. | 2 | $41 |
| Bausch Health US, LLC | 2 | $31 |
| Corium, LLC | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$430
- INVEGA SUSTENNA$237
- VRAYLAR$233
- INVEGA TRINZA$134
- DARZALEX$132
- TECVAYLI$132
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- UZEDY$125
- UPTRAVI$114
- OPSUMIT$114
- ARISTADA INITIO$107
How this compares
$9,916 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $375,554 |
| Invega SustennaPaliperidone Palmitate | 74 | $208,673 |
| IngrezzaValbenazine Tosylate | 12 | $102,362 |
| Invega TrinzaPaliperidone Palmitate | 11 | $101,173 |
| VraylarCariprazine Hcl | 29 | $48,652 |
| Abilify MaintenaAripiprazole | 17 | $45,061 |
| VivitrolNaltrexone Microspheres | 24 | $38,544 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $37,062 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $25,014 |
| RexultiBrexpiprazole | 12 | $17,232 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 76 | $13,471 |
| ConcertaMethylphenidate Hcl | 11 | $4,508 |
| Clozapine | 47 | $3,503 |
| Paliperidone ErPaliperidone | 30 | $2,139 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $1,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,649 | $375,55434 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Concerta | $1,003 | $314,35496 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,045 | $102,36212 claims |
| Alkermes, Inc.Vivitrol, Lybalvi | $1,170 | $63,55739 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $466 | $62,29329 claims |
| AbbVieVraylar | $1,466 | $48,65229 claims |
| Indivior Inc.Suboxone | $151 | $37,06252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.
Other medical in Durham
- Colleen PrinceDurham$19K
- Jenna BrothersDurham$10K
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$265K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.